Nexalin Technology, Inc. (NXL)
NASDAQ: NXL · IEX Real-Time Price · USD
1.625
-0.005 (-0.31%)
At close: Apr 23, 2024, 4:00 PM
1.590
-0.035 (-2.15%)
After-hours: Apr 23, 2024, 6:48 PM EDT
Company Description
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China.
It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia.
The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders.
In addition, it designs and develops Generation 2 and Generation 3, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, Alzheimer's disease, and dementia.
The company is based in Houston, Texas.
Nexalin Technology, Inc.
| Country | United States |
| Founded | 2010 |
| IPO Date | Sep 16, 2022 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Mark White |
Contact Details
Address: 1776 Yorktown, Suite 550 Houston, Texas 77056 United States | |
| Phone | (832) 260-0222 |
| Website | nexalin.com |
Stock Details
| Ticker Symbol | NXL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.15 |
| CIK Code | 0001527352 |
| CUSIP Number | 65345B201 |
| ISIN Number | US65345B2016 |
| Employer ID | 27-5566468 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Marilyn Elson | Controller |
| Mark White | President, Chief Executive Officer, Chief Financial Officer and Director |
| John Patrick Claude | Co-Founder and Director of Engineering and Development |
| Dr. David Owens M.D. | Chief Medical Officer and Director |
| Michael Nketiah | Senior Vice-President of Quality, Regulatory and Clinical Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Apr 11, 2024 | 8-K | Current Report |
| Mar 27, 2024 | 10-K | Annual Report |
| Mar 20, 2024 | 8-K | Current Report |
| Jan 17, 2024 | DEF 14A | Other definitive proxy statements |
| Nov 13, 2023 | 10-Q | Quarterly Report |
| Nov 13, 2023 | 8-K | Current Report |
| Oct 6, 2023 | DEF 14A | Other definitive proxy statements |
| Sep 28, 2023 | 8-K | Current Report |
| Aug 10, 2023 | 10-Q | Quarterly Report |